logo
Share SHARE
FONT-SIZE Plus   Neg

Regeneron Says Australian TGA Granted Approval For EYLEA To Bayer Healthcare

Regeneron Pharmaceuticals Inc (REGN) along with Bayer Healthcare announced on Thursday that the Australian Therapeutic Goods Administration or the TGA has granted approval to Bayer Healthcare for EYLEA injection.

The EYLEA injection is for the treatment of patients with neovascular age-related macular degeneration at a recommended dose of 2 milligrams via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months.

EYLEA Injection, known in the scientific literature as VEGF Trap-Eye, is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. EYLEA acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF) and thereby can inhibit the binding and activation of these cognate VEGF receptors.

"The approval of EYLEA represents an important new option for wet AMD patients in Australia," said George D Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories. "EYLEA allows for clinical efficacy that is non-inferior to monthly ranibizumab, but with fewer injections and less frequent office visits. We believe that this may help reduce treatment challenges for wet AMD patients and their physicians in Australia."

Bayer Healthcare plans to launch EYLEA in Australia in the second half 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cable-cutters have now one more reason to do so as live television streaming will be available on YouTube TV in 14 more markets in the U.S. Facebook Chief Operating Officer Sheryl Sandberg has donated nearly $100 million in Facebook shares to charity. This is her second charitable donation within a year. A document was filed on Thursday with the Security and Exchange Commission, which shows that Sandberg transferred shares to a special fund she uses for charitable donations. Ford Motor Co.'s new CEO Jim Hackett has taken a more cautious approach to the automaker's plans for rolling out autonomous vehicles. Ford is currently undertaking a 100-day review of its operations and Hackett indicated at delays to the company's plans to launch a fully-autonomous vehicle by 2021.
comments powered by Disqus
Follow RTT